🇺🇸 FDA
Pipeline program

EDG-7500

EDG-7500-102

Phase 2 small_molecule active

Quick answer

EDG-7500 for Hypertrophic Cardiomyopathy is a Phase 2 program (small_molecule) at Edgewise Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Edgewise Therapeutics
Indication
Hypertrophic Cardiomyopathy
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials